Clinical Trial Update: A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes [Phase 1, Phase 2]

View source ↗

Summary

A 6-week PK/PD, safety and tolerability study of GK1-399 in type 2 diabetes (Phase 1/2) has been completed. The trial was sponsored by vTv Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GK1-399

Snippet

Sponsor: vTv Therapeutics | Conditions: Type 2 Diabetes Mellitus | Phase 1, Phase 2 | Status: COMPLETED